@phdthesis{GernertgebBaranski2017,
  author    = {Gernert [geb. Baranski], Stefanie},
  title     = {Assoziationsuntersuchung zu Neuropeptid Y-Polymorphismen bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivit{\"a}tsst{\"o}rung},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-155692},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2017},
  abstract  = {Die Aufmerksamkeitsdefizit-/Hyperaktivit{\"a}tsst{\"o}rung ist eine der h{\"a}ufigsten psychiatrischen Erkrankung des Kindesalters, die eine hohe Heritabilit{\"a}t aufweist und h{\"a}ufig bis ins Erwachsenenalter persistiert und lebenslang zu sozialen, gesundheitlichen und {\"o}konomischen Problemen f{\"u}hrt. Die ADHS tritt bei vielen Patienten in Kombina-tion mit anderen psychiatrischen und nicht-psychiatrischen Erkrankungen auf. In den letzten Jahren r{\"u}ckte zunehmend die h{\"a}ufig zur ADHS komorbid auftretende Adipositas in den Fokus der Forschung. Auf der Suche nach copy number variations in Zusammenhang mit ADHS, wurde eine Duplikation auf Chromosom 7p15 - dem Genlocus des NPY - entdeckt. NPY, ist ein endogenes orexigenes Peptid, welches physiologischerweise die Nahrungsaufnahme stimuliert und neben zahlreichen Effekten, wie Blutdruck- und Knochenregulation, auch in Zusammenhang mit neuropsychiatrischen Erkrankungen gebracht werden konnte. Diese Duplikation auf einem Genort, dessen Produkt f{\"u}r die Regulation von Energiehaushalt und K{\"o}rpergewicht zust{\"a}ndig ist, bildete die Grundlage, eine Assoziationsuntersuchung zu NPY-Genvarianten und dem K{\"o}rpergewicht bei Kindern durchzuf{\"u}hren. Untersucht wurden bei 269 an ADHS erkrankten Kindern und 142 gesunden Kontrollkindern die Assoziation zwischen NPY-Genvarianten (rs16147, rs16139, rs5574, rs16124) und ADHS, sowie die Assoziation zwischen NPY-Genvarianten und BMI-Perzentilen bei ADHS. Es ergab sich keine signifikante Assoziation bez{\"u}glich der aufgestellten Hypothesen.},
  subject      = {{\"U}bergewicht},
  language  = {de}
}
@article{GottschalkRichterZiegleretal.2019,
  author    = {Gottschalk, Michael G. and Richter, Jan and Ziegler, Christiane and Schiele, Miriam A. and Mann, Julia and Geiger, Maximilian J. and Schartner, Christoph and Homola, Gy{\"o}rgy A. and Alpers, Georg W. and B{\"u}chel, Christian and Fehm, Lydia and Fydrich, Thomas and Gerlach, Alexander L. and Gloster, Andrew T. and Helbig-Lang, Sylvia and Kalisch, Raffael and Kircher, Tilo and Lang, Thomas and Lonsdorf, Tina B. and Pan{\´e}-Farr{\´e}, Christiane A. and Str{\"o}hle, Andreas and Weber, Heike and Zwanzger, Peter and Arolt, Volker and Romanos, Marcel and Wittchen, Hans-Ulrich and Hamm, Alfons and Pauli, Paul and Reif, Andreas and Deckert, J{\"u}rgen and Neufang, Susanne and H{\"o}fler, Michael and Domschke, Katharina},
  title     = {Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes},
  series = {Translational Psychiatry},
  volume    = {9},
  journal   = {Translational Psychiatry},
  doi       = {10.1038/s41398-019-0415-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227479},
  year      = {2019},
  abstract  = {Preclinical studies point to a pivotal role of the orexin 1 (OX1) receptor in arousal and fear learning and therefore suggest the HCRTR1 gene as a prime candidate in panic disorder (PD) with/without agoraphobia (AG), PD/AG treatment response, and PD/AG-related intermediate phenotypes. Here, a multilevel approach was applied to test the non-synonymous HCRTR1 C/T Ile408Val gene variant (rs2271933) for association with PD/AG in two independent case-control samples (total n = 613 cases, 1839 healthy subjects), as an outcome predictor of a six-weeks exposure-based cognitive behavioral therapy (CBT) in PD/AG patients (n = 189), as well as with respect to agoraphobic cognitions (ACQ) (n = 483 patients, n = 2382 healthy subjects), fMRI alerting network activation in healthy subjects (n = 94), and a behavioral avoidance task in PD/AG pre- and post-CBT (n = 271). The HCRTR1 rs2271933 T allele was associated with PD/AG in both samples independently, and in their meta-analysis (p = 4.2 × 10-7), particularly in the female subsample (p = 9.8 × 10-9). T allele carriers displayed a significantly poorer CBT outcome (e.g., Hamilton anxiety rating scale: p = 7.5 × 10-4). The T allele count was linked to higher ACQ sores in PD/AG and healthy subjects, decreased inferior frontal gyrus and increased locus coeruleus activation in the alerting network. Finally, the T allele count was associated with increased pre-CBT exposure avoidance and autonomic arousal as well as decreased post-CBT improvement. In sum, the present results provide converging evidence for an involvement of HCRTR1 gene variation in the etiology of PD/AG and PD/AG-related traits as well as treatment response to CBT, supporting future therapeutic approaches targeting the orexin-related arousal system.},
  language  = {en}
}
@phdthesis{Graefe2011,
  author    = {Gr{\"a}fe, Catherin},
  title     = {Familienuntersuchung bei Kindern und Jugendlichen mit ADHS - Unterschiede der DSM-IV Subtypen bez{\"u}glich Komorbidit{\"a}t, famili{\"a}rer Belastung und Krankheitsbeginn},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-57370},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Im Rahmen der vorliegenden Arbeit wurden Unterschiede zwischen dem vorwiegend unaufmerksamen und dem kombinierten Subtyp nach DSM-IV anhand von Familien, in denen mindestens zwei Kinder von ADHS betroffen sind, untersucht. Die famili{\"a}re Betroffenheit, Art und Anzahl der komorbiden St{\"o}rungen sowie der Diagnosezeitpunkt wurden bez{\"u}glich der Unterschiede zwischen den Subtypen analysiert. Weiterhin wurden epidemiologische und soziodemographische Merkmale beschrieben. Methodik: Im Rahmen einer Multicenterstudie wurden 250 Kinder sowie deren Eltern aus 116 Familien untersucht. ADHS und Komorbidit{\"a}ten wurden anhand des K-SADS-PL und DIKJ erhoben. Bei den Eltern wurde ADHS anhand der Wender-Utah-Rating-Scale (WURS) und der Barkley-Skalen ermittelt. Ergebnisse: Bei 39\% der an ADHS erkrankten Kinder und Jugendlichen lag zus{\"a}tzlich mindestens eine komorbide St{\"o}rung zum Zeitpunkt der Untersuchung vor. Die Annahme, dass der kombinierte Subtyp mit einer h{\"o}heren famili{\"a}ren Belastung einhergeht, konnte im Rahmen der Studie nicht best{\"a}tigt werden. Verglichen mit den einfachen Subtypen zeigte sich keine st{\"a}rkere Betroffenheit von Komorbidit{\"a}ten beim kombinierten Subtyp. Patienten, die vom kombinierten Subtyp betroffen waren, hatten signifikant h{\"a}ufiger komorbide externalisierende St{\"o}rungen als Patienten, bei denen ein einfacher Subtyp diagnostiziert worden war. Diese Studie best{\"a}tigte die Annahme, dass Patienten, bei denen ein unaufmerksamer Subtyp diagnostiziert worden war, signifikant h{\"a}ufiger an komorbiden internalisierenden St{\"o}rungen litten und sich verglichen mit den anderen Subtypen durch einen sp{\"a}teren Diagnosezeitpunkt auszeichneten.},
  subject      = {ADHS},
  language  = {de}
}
@article{GruenblattOnedaEkicietal.2017,
  author    = {Gr{\"u}nblatt, Edna and Oneda, Beatrice and Ekici, Arif B. and Ball, Juliane and Geissler, Julia and Uebe, Steffen and Romanos, Marcel and Rauch, Anita and Walitza, Susanne},
  title     = {High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder},
  series = {BMC Medical Genomics},
  volume    = {10},
  journal   = {BMC Medical Genomics},
  number    = {68},
  doi       = {10.1186/s12920-017-0299-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-172791},
  year      = {2017},
  abstract  = {Background Obsessive-Compulsive Disorder (OCD) is a common and chronic disorder in which a person has uncontrollable, reoccurring thoughts and behaviours. It is a complex genetic condition and, in case of early onset (EO), the patients manifest a more severe phenotype, and an increased heritability. Large (>500 kb) copy number variations (CNVs) previously associated with autism and schizophrenia have been reported in OCD. Recently, rare CNVs smaller than 500 kb overlapping risk loci for other neurodevelopmental conditions have also been reported in OCD, stressing the importance of examining CNVs of any size range. The aim of this study was to further investigate the role of rare and small CNVs in the aetiology of EO-OCD. Methods We performed high-resolution chromosomal microarray analysis in 121 paediatric OCD patients and in 124 random controls to identify rare CNVs (>50 kb) which might contribute to EO-OCD. Results The frequencies and the size of the observed rare CNVs in the patients did not differ from the controls. However, we observed a significantly higher frequency of rare CNVs affecting brain related genes, especially deletions, in the patients (OR = 1.98, 95\% CI 1.02-3.84; OR = 3.61, 95\% CI 1.14-11.41, respectively). Similarly, enrichment-analysis of CNVs gene content, performed with three independent methods, confirmed significant clustering of predefined genes involved in synaptic/brain related functional pathways in the patients but not in the controls. In two patients we detected \(de-novo\) CNVs encompassing genes previously associated with different neurodevelopmental disorders \(\textit{NRXN1, ANKS1B, UHRF1BP1}\)). Conclusions Our results further strengthen the role of small rare CNVs, particularly deletions, as susceptibility factors for paediatric OCD.},
  language  = {en}
}
@article{GschmackMonoranuMaroufetal.2022,
  author    = {Gschmack, Eva and Monoranu, Camelia-Maria and Marouf, Hecham and Meyer, Sarah and Lessel, Lena and Idris, Raja and Berg, Daniela and Maetzler, Walter and Steigerwald, Frank and Volkmann, Jens and Gerlach, Manfred and Riederer, Peter and Koutsilieri, Eleni and Scheller, Carsten},
  title     = {Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease},
  series = {Journal of Neural Transmission},
  volume    = {129},
  journal   = {Journal of Neural Transmission},
  number    = {5-6},
  doi       = {10.1007/s00702-022-02495-4},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325161},
  pages     = {545-555},
  year      = {2022},
  abstract  = {Idiopathic Parkinson's disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus-subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood-brain barrier.},
  language  = {en}
}
@phdthesis{Goessler2007,
  author    = {G{\"o}ßler, Michael},
  title     = {Molekulargenetische Untersuchungen serotonerger Kandidatengene bei Zwangsst{\"o}rungen im Kindes- und Jugendalter},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-23773},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2007},
  abstract  = {Zwangsst{\"o}rungen, im englischen als Obsessive Compulsive Disorder (OCD) bezeichnet, sind sowohl in der Erwachsenen- als auch in der Kinder- und Jugendpsychiatrie bekannte Krankheitsbilder, die mit einer Lebenszeitpr{\"a}valenz von 2,5 - 3\% zu den h{\"a}ufigsten psychiatrischen Erkrankungen im Kindes- und Jugendalter geh{\"o}ren. Sie stellen in der Regel eine erhebliche Belastung sowohl f{\"u}r die betroffenen Kinder als auch f{\"u}r deren Familie dar und schr{\"a}nken den allt{\"a}glichen Lebensablauf je nach Auspr{\"a}gung erheblich ein. Familien- und Zwillingsuntersuchungen zeigen, dass bei Zwangsst{\"o}rungen eine deutliche famili{\"a}re Belastung vorliegt. Gerade bei einer fr{\"u}hen Manifestation im Kindesalter (auf englisch als early onset bezeichnet) konnten Familienstudien zeigen, dass genetische Faktoren eine besonders ausgepr{\"a}gte Rolle spielen. Diese formalgenetischen Studien legen weitere Untersuchungen auf molekulargenetischer Ebene f{\"u}r Zwangsst{\"o}rungen im Kindes- und Jugendalter nahe. Pharmakologische Studien und erste molekulargenetische Studien verweisen zudem auf einen Zusammenhang zwischen Zwangs- und Angstsymptomen und dem Serotoninstoffwechsel. Selektive Serotonin Wiederaufnahme-Hemmer (Selective Serotonine Reuptake Inhibitors, SSRI) und tricyclische Antidepressiva sind bei der Behandlung von Zwangsst{\"o}rungen besonders wirksam. Auch im Kindes- und Jugendalter sind diese Medikamente aufgrund ihrer positiven Wirkung bei Zwangsst{\"o}rungen Mittel der ersten Wahl. Insgesamt wird die Pathogenese der Zwangsst{\"o}rungen nach aktuellem Forschungsstand als multifaktoriell angenommen. Dabei bezieht sich bisher die {\"u}berwiegende Zahl der Untersuchungen auf Zwangsst{\"o}rungen erwachsener Patienten. Nach aktuellem Kenntnisstand handelt es sich bei der vorliegenden Arbeit um die ersten familienbasierten Assoziationsstudien bei Kindern und Jugendlichen mit Zwangsst{\"o}rungen. Zielsetzung dieser Arbeit war die Untersuchung einer Assoziation von Varianten in ausgew{\"a}hlten Genen des serotonergen Systems und juvenilen Zwangsst{\"o}rungen. Die Auswahl der Kandidatengene f{\"u}r Zwangsst{\"o}rungen erfolgte auf patho-physiologischen {\"U}berlegungen: Die Tryptophanhydroxylase als geschwindigkeits-bestimmendes Enzym in der Synthese von Serotonin, der Serotonin-1B-Rezeptor als Zielorgan mit autoregulierender Funktion auf das serotonerge System, sowie der Serotonintransporter, der, therapeutisch genutzt, von SSRIs blockiert wird. Untersuchungen zu den genannten Kandidatengenen liegen bei erwachsenen Patienten mit Zwangsst{\"o}rungen vor, die Ergebnisse sollten in unserer Studie repliziert werden. 64 Kinder und Jugendliche, sowie deren leibliche Eltern wurden in die Untersuchung eingeschlossen. In den vorliegenden molekulargenetischen Untersuchungen konnten f{\"u}r Varianten im Tryptophanhydroxylase-1-Gen und dem Serotonin-1B-Rezeptor-Gen kein Zusammenhang mit Zwangsst{\"o}rungen bei Kindern und Jugendlichen gesehen werden. Die funktionelle Variante des Serotonintransporter-Gens, die zu einer h{\"o}heren Aktivit{\"a}t des Transporters f{\"u}hrt, wurde tendenziell h{\"a}ufiger bei den Patienten mit Zwangsst{\"o}rungen beobachtet. Der Befund entspricht damit in der Richtung den fr{\"u}heren Befunden von erwachsenen Patienten.},
  language  = {de}
}
@article{HammerleHussErnstetal.2016,
  author    = {Hammerle, Florian and Huss, Michael and Ernst, Verena and B{\"u}rger, Arne},
  title     = {Thinking dimensional: prevalence of DSM-5 early adolescent full syndrome, partial and subthreshold eating disorders in a cross-sectional survey in German schools},
  series = {BMJ Open},
  volume    = {6},
  journal   = {BMJ Open},
  number    = {e010843},
  doi       = {10.1136/bmjopen-2015-010843},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-164734},
  year      = {2016},
  abstract  = {Objectives Investigating for the first time in Germany Diagnostic and Statistical Manual Fifth Edition (DSM-5) prevalences of adolescent full syndrome, Other Specified Feeding or Eating Disorder (OSFED), partial and subthreshold anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED). Method A national school-based cross-sectional survey with nine schools in Germany was undertaken that was aimed at students from grades 7 and 8. Of the 1775 students who were contacted to participate in the study, 1654 participated (participation rate: 93.2\%). The sample consisted of 873 female and 781 male adolescents (mean age=13.4 years). Prevalence rates were established using direct symptom criteria with a structured inventory (SIAB-S) and an additional self-report questionnaire (Eating Disorder Inventory 2 (EDI-2)). Results Prevalences for full syndrome were 0.3\% for AN, 0.4\% for BN, 0.5\% for BED and 3.6\% for OSFED-atypical AN, 0\% for BN (low frequency/limited duration), 0\% for BED (low frequency/limited duration) and 1.9\% for purging disorder (PD). Prevalences of partial syndrome were 10.9\% for AN (7.1\% established with cognitive symptoms only, excluding weight criteria), 0.2\% for BN and 2.1\% for BED, and of subthreshold syndrome were 0.8\% for AN, 0.3\% for BN and 0.2\% for BED. Cases on EDI-2 scales were much more pronounced with 12.6-21.1\% of the participants with significant sex differences. Conclusions The findings were in accordance with corresponding international studies but were in contrast to other German studies showing much higher prevalence rates. The study provides, for the first time, estimates for DSM-5 prevalences of eating disorders in adolescents for Germany, and evidence in favour of using valid measures for improving prevalence estimates."},
  language  = {en}
}
@article{HautmannDoepfnerKatzmannetal.2018,
  author    = {Hautmann, Christopher and D{\"o}pfner, Manfred and Katzmann, Josepha and Sch{\"u}rmann, Stephanie and Wolff Metternich-Kaizman, Tanja and Jaite, Charlotte and Kappel, Viola and Geissler, Julia and Warnke, Andreas and Jacob, Christian and Hennighausen, Klaus and Haack-Dees, Barbara and Schneider-Momm, Katja and Philipsen, Alexandra and Matthies, Swantje and R{\"o}sler, Michael and Retz, Wolfgang and Gontard, Alexander von and Sobanski, Esther and Alm, Barbara and Hohmann, Sarah and H{\"a}ge, Alexander and Poustka, Luise and Colla, Michael and Gentschow, Laura and Freitag, Christine M. and Becker, Katja and Jans, Thomas},
  title     = {Sequential treatment of ADHD in mother and child (AIMAC study): importance of the treatment phases for intervention success in a randomized trial},
  series = {BMC Psychiatry},
  volume    = {18},
  journal   = {BMC Psychiatry},
  doi       = {10.1186/s12888-018-1963-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227930},
  year      = {2018},
  abstract  = {Background The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment. Methods The analysis included 143 mothers and children (aged 6-12 years) both diagnosed with ADHD. The study design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: intensive treatment of the mother including psychotherapy and pharmacotherapy; Step 1 control group [CG]: supportive counseling only for mother; Step 2 TG and CG: PCT). Single- and multi-group analyses with piecewise linear latent growth curve models were applied to test for the effects of group and phase. Child symptoms (e.g., ADHD symptoms, disruptive behavior) were rated by three informants (blinded clinician, mother, teacher). Results Children in the TG showed a stronger improvement of their disruptive behavior as rated by mothers than those in the CG during Step 1 (Step 1: TG vs. CG). In the CG, according to reports of the blinded clinician and the mother, the reduction of children's disruptive behavior was stronger during Step 2 than during Step 1 (CG: Step 1 vs. Step 2). In the TG, improvement of child outcome did not differ across treatment steps (TG: Step 1 vs. Step 2). Conclusions Intensive treatment of the mother including pharmacotherapy and psychotherapy may have small positive effects on the child's disruptive behavior. PCT may be a valid treatment option for children with ADHD regarding disruptive behavior, even if mothers are not intensively treated beforehand. Trial registration ISRCTN registry ISRCTN73911400. Registered 29 March 2007.},
  language  = {en}
}
@article{HavikDegenhardtJohanssonetal.2012,
  author    = {Havik, Bjarte and Degenhardt, Franziska A. and Johansson, Stefan and Fernandes, Carla P. D. and Hinney, Anke and Scherag, Andr{\´e} and Lybaek, Helle and Djurovic, Srdjan and Christoforou, Andrea and Ersland, Kari M. and Giddaluru, Sudheer and O'Donovan, Michael C. and Owen, Michael J. and Craddock, Nick and M{\"u}hleisen, Thomas W. and Mattheisen, Manuel and Schimmelmann, Benno G. and Renner, Tobias and Warnke, Andreas and Herpertz-Dahlmann, Beate and Sinzig, Judith and Albayrak, {\"O}zg{\"u}r and Rietschel, Marcella and N{\"o}then, Markus M. and Bramham, Clive R. and Werge, Thomas and Hebebrand, Johannes and Haavik, Jan and Andreassen, Ole A. and Cichon, Sven and Steen, Vidar M. and Le Hellard, Stephanie},
  title     = {DCLK1 Variants Are Associated across Schizophrenia and Attention Deficit/Hyperactivity Disorder},
  series = {PLoS One},
  volume    = {7},
  journal   = {PLoS One},
  number    = {4},
  doi       = {10.1371/journal.pone.0035424},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135285},
  pages     = {e35424},
  year      = {2012},
  abstract  = {Doublecortin and calmodulin like kinase 1 (DCLK1) is implicated in synaptic plasticity and neurodevelopment. Genetic variants in DCLK1 are associated with cognitive traits, specifically verbal memory and general cognition. We investigated the role of DCLK1 variants in three psychiatric disorders that have neuro-cognitive dysfunctions: schizophrenia (SCZ), bipolar affective disorder (BP) and attention deficit/hyperactivity disorder (ADHD). We mined six genome wide association studies (GWASs) that were available publically or through collaboration; three for BP, two for SCZ and one for ADHD. We also genotyped the DCLK1 region in additional samples of cases with SCZ, BP or ADHD and controls that had not been whole-genome typed. In total, 9895 subjects were analysed, including 5308 normal controls and 4,587 patients (1,125 with SCZ, 2,496 with BP and 966 with ADHD). Several DCLK1 variants were associated with disease phenotypes in the different samples. The main effect was observed for rs7989807 in intron 3, which was strongly associated with SCZ alone and even more so when cases with SCZ and ADHD were combined (P-value = 4x10\(^{-5}\) and 4x10\(^{-6}\), respectively). Associations were also observed with additional markers in intron 3 (combination of SCZ, ADHD and BP), intron 19 (SCZ+BP) and the 3'UTR (SCZ+BP). Our results suggest that genetic variants in DCLK1 are associated with SCZ and, to a lesser extent, with ADHD and BP. Interestingly the association is strongest when SCZ and ADHD are considered together, suggesting common genetic susceptibility. Given that DCLK1 variants were previously found to be associated with cognitive traits, these results are consistent with the role of DCLK1 in neurodevelopment and synaptic plasticity.},
  language  = {en}
}
@article{HebestreitZeidlerSchippersetal.2022,
  author    = {Hebestreit, Helge and Zeidler, Cornelia and Schippers, Christopher and de Zwaan, Martina and Deckert, J{\"u}rgen and Heuschmann, Peter and Krauth, Christian and Bullinger, Monika and Berger, Alexandra and Berneburg, Mark and Brandstetter, Lilly and Deibele, Anna and Dieris-Hirche, Jan and Graessner, Holm and G{\"u}ndel, Harald and Herpertz, Stephan and Heuft, Gereon and Lapstich, Anne-Marie and L{\"u}cke, Thomas and Maisch, Tim and Mundlos, Christine and Petermann-Meyer, Andrea and M{\"u}ller, Susanne and Ott, Stephan and Pfister, Lisa and Quitmann, Julia and Romanos, Marcel and Rutsch, Frank and Schaubert, Kristina and Schubert, Katharina and Schulz, J{\"o}rg B. and Schweiger, Susann and T{\"u}scher, Oliver and Ungeth{\"u}m, Kathrin and Wagner, Thomas O. F. and Haas, Kirsten},
  title     = {Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {17},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {1},
  doi       = {10.1186/s13023-022-02176-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300440},
  year      = {2022},
  abstract  = {Background In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. Study design This multi-center, prospective controlled study has a two-phase cohort design. Methods Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD's outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). Outcomes Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30\% in standard care to 40\% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients' quality of life and evaluation of care; and f) physicians' satisfaction with the innovative care approach. Conclusions This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease.},
  language  = {en}
}